Thu, Jan 29, 2015, 5:00 AM EST - U.S. Markets open in 4 hrs 30 mins


% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

  • jlymd jlymd Mar 21, 2004 4:31 PM Flag


    With all due respect to Chris Jenner whose a smart guy, I don't see from a valuation perspective that 1B in Indiplon sales translates to triple the share price. Someone can correct me but I believe the split with Pfizer was closer to 50:50 and even at that royalty rate, a price above 70/share doesn't seem warranted. The value of the rest of the pipeline at this point doesn't warrant it either. Results of the 6-month open label efficacy study in elderly pts is due Q104

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This is a stock that will trade @50 to 60 times earnings, so a $120M to the bottom line will do just that. Thats about a $6 Billion market cap on $500M in sales after 50/50 split on a $1 Billion in sales projected by FY2007. Projections on the seize of the insomnia market is $5 Billion by FY2010. So IMO Indiplon could have sales in the $2 Billion range by FY2010.

      • 1 Reply to frogsleapmerlot
      • Keep in mind, NBIX is a 1-trick pony biotech for the forseeable future. The number of BTs with 1 product that can carry a 60 multiple are limited, the reason being the discount the street needs to afford a company with that kind of business risk. Even with PFE as a partner, the chances of Indiplon ramping to 1B in sales in 3 years with Estorra, Ambien MR and generic Ambien on the market is at best a stretch.

33.39-0.15(-0.45%)Jan 28 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.